A5049775340- Virus-based gene therapy research
- Renal and related cancers
- Parvovirus B19 Infection Studies
- Energy Harvesting in Wireless Networks
- Glioma Diagnosis and Treatment
- Cancer Research and Treatments
- Cerebrospinal fluid and hydrocephalus
- Spinal Dysraphism and Malformations
- Head and Neck Surgical Oncology
- Microtubule and mitosis dynamics
- Traumatic Brain Injury and Neurovascular Disturbances
- Cancer, Hypoxia, and Metabolism
- Adrenal and Paraganglionic Tumors
- Congenital gastrointestinal and neural anomalies
- Fetal and Pediatric Neurological Disorders
- Hereditary Neurological Disorders
- S100 Proteins and Annexins
- Respiratory Support and Mechanisms
- CAR-T cell therapy research
- Venous Thromboembolism Diagnosis and Management
- Cerebral Venous Sinus Thrombosis
- Nanoparticle-Based Drug Delivery
Erasmus MC
2014-2023
Erasmus MC Cancer Institute
2023
University of Amsterdam
2023
Erasmus University Rotterdam
2008-2016
Abstract Purpose: Testing safety of Delta24-RGD (DNX-2401), an oncolytic adenovirus, locally delivered by convection enhanced delivery (CED) in tumor and surrounding brain patients with recurrent glioblastoma. Patients Methods: Dose-escalation phase I study 3+3 cohorts, dosing 107 to 1 × 1011 viral particles (vp) 20 patients. Besides clinical parameters, adverse events, radiologic findings, blood, cerebrospinal fluid (CSF), interstitial fluid, excreta were sampled over time analyzed for...
Abstract Background External ventricular drainage (EVD) is frequently used in neurosurgical procedures for cerebrospinal fluid (CSF) drainage. It is, however, associated with high infection rates, namely secondary meningitis and ventriculitis. Based on a previous prevalence of these infections among patients EVDs, we have proposed implemented protocol an effort to decrease the rate. The aim this study was measure effect hospital-wide implementation EVD handling infections. Patients methods...
Background: This Phase 1 study evaluates the intra- and peritumoral administration by convection enhanced delivery (CED) of human recombinant Bone Morphogenetic Protein 4 (hrBMP4), a protein that stimulates differentiation cancer stem cells (CSCs), in patients with recurrent glioblastoma.Methods: In 3+3 dose escalation design, glioblastoma received one five levels hrBMP4 CED over to 6 days. The ranged from total 0∙5 18 mg. Patients were followed periodic physical neurologic examinations,...
Supplementary Data from Convection Enhanced Delivery of the Oncolytic Adenovirus Delta24-RGD in Patients with Recurrent GBM: A Phase I Clinical Trial Including Correlative Studies
Supplementary Figure from Convection Enhanced Delivery of the Oncolytic Adenovirus Delta24-RGD in Patients with Recurrent GBM: A Phase I Clinical Trial Including Correlative Studies
Supplementary Figure from Convection Enhanced Delivery of the Oncolytic Adenovirus Delta24-RGD in Patients with Recurrent GBM: A Phase I Clinical Trial Including Correlative Studies
Supplementary Figure from Convection Enhanced Delivery of the Oncolytic Adenovirus Delta24-RGD in Patients with Recurrent GBM: A Phase I Clinical Trial Including Correlative Studies
<div>AbstractPurpose:<p>Testing safety of Delta24-RGD (DNX-2401), an oncolytic adenovirus, locally delivered by convection enhanced delivery (CED) in tumor and surrounding brain patients with recurrent glioblastoma.</p>Patients Methods:<p>Dose-escalation phase I study 3+3 cohorts, dosing 10<sup>7</sup> to 1 × 10<sup>11</sup> viral particles (vp) 20 patients. Besides clinical parameters, adverse events, radiologic findings, blood, cerebrospinal...
Supplementary Figure from Convection Enhanced Delivery of the Oncolytic Adenovirus Delta24-RGD in Patients with Recurrent GBM: A Phase I Clinical Trial Including Correlative Studies
Supplementary Figure from Convection Enhanced Delivery of the Oncolytic Adenovirus Delta24-RGD in Patients with Recurrent GBM: A Phase I Clinical Trial Including Correlative Studies
Supplementary Figure from Convection Enhanced Delivery of the Oncolytic Adenovirus Delta24-RGD in Patients with Recurrent GBM: A Phase I Clinical Trial Including Correlative Studies
Supplementary Figure from Convection Enhanced Delivery of the Oncolytic Adenovirus Delta24-RGD in Patients with Recurrent GBM: A Phase I Clinical Trial Including Correlative Studies
Supplementary Figure from Convection Enhanced Delivery of the Oncolytic Adenovirus Delta24-RGD in Patients with Recurrent GBM: A Phase I Clinical Trial Including Correlative Studies
Supplementary Figure from Convection Enhanced Delivery of the Oncolytic Adenovirus Delta24-RGD in Patients with Recurrent GBM: A Phase I Clinical Trial Including Correlative Studies
Supplementary Data from Convection Enhanced Delivery of the Oncolytic Adenovirus Delta24-RGD in Patients with Recurrent GBM: A Phase I Clinical Trial Including Correlative Studies
<div>AbstractPurpose:<p>Testing safety of Delta24-RGD (DNX-2401), an oncolytic adenovirus, locally delivered by convection enhanced delivery (CED) in tumor and surrounding brain patients with recurrent glioblastoma.</p>Patients Methods:<p>Dose-escalation phase I study 3+3 cohorts, dosing 10<sup>7</sup> to 1 × 10<sup>11</sup> viral particles (vp) 20 patients. Besides clinical parameters, adverse events, radiologic findings, blood, cerebrospinal...
Supplementary Figure from Convection Enhanced Delivery of the Oncolytic Adenovirus Delta24-RGD in Patients with Recurrent GBM: A Phase I Clinical Trial Including Correlative Studies
Supplementary Figure from Convection Enhanced Delivery of the Oncolytic Adenovirus Delta24-RGD in Patients with Recurrent GBM: A Phase I Clinical Trial Including Correlative Studies
Supplementary Figure from Convection Enhanced Delivery of the Oncolytic Adenovirus Delta24-RGD in Patients with Recurrent GBM: A Phase I Clinical Trial Including Correlative Studies
Supplementary Figure from Convection Enhanced Delivery of the Oncolytic Adenovirus Delta24-RGD in Patients with Recurrent GBM: A Phase I Clinical Trial Including Correlative Studies
Supplementary Figure from Convection Enhanced Delivery of the Oncolytic Adenovirus Delta24-RGD in Patients with Recurrent GBM: A Phase I Clinical Trial Including Correlative Studies